SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
54.60    -1.40 (-2.50%)
Bid:
52.60
Ask:
56.60
Spread: 4.00 (7.605%)
Market Cap: £45.60m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Statement

19 May 2008 13:30

RNS Number : 7780U
Flomerics Group PLC
19 May 2008
 



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATESAUSTRALIACANADA OR JAPAN

FOR IMMEDIATE RELEASE

19th May 2008

FLOMERICS GROUP PLC

Statement re: Posting of Offer Document following Unsolicited Offer

 

 

The Board of Directors of Flomerics Group PLC ("Flomerics" or the "Company") notes the statement by Mentor Graphics, Inc. ("Mentor") that it has posted an offer document to Flomerics shareholders in respect of its unsolicited offer for all the outstanding shares and stock options in Flomerics at a price of 104 pence per share payable in cash (the "Offer"). 

 

The Board of Directors of Flomerics continues to believe the Offer materially undervalues the Company and is actively engaged in assessing other alternatives available to the Company, including potential interest expressed by a number of other parties, which are the subject of ongoing discussions. Shareholders are therefore strongly urged to ignore any documents or announcements that may be made or issued by Mentor or its advisers and not to sell their valuable Flomerics shares.

David Mann, Chairman of Flomerics commented: "We have previously stated that the Offer, which is unsolicited, has been considered by the Board of Flomerics, in conjunction with its independent adviser, and we have unanimously concluded that it does not reflect the true value of Flomerics shares. As such, the Offer does not carry the recommendation of the Flomerics Board of Directors as we do not believe it is in the best interests of Flomerics shareholders." 

The Board of Directors intends to write to its shareholders in due course to explain its current position with regard to the Mentor Offer.

Any discussions with other interested parties continue to be at an early stage and there can be no certainty that an alternative offer will be forthcoming. However, shareholders are strongly recommended to take no action at this stage. A further announcement will be made in due course.

 

Enquiries: 

 

Flomerics Group PLC

Gary Carter

Keith Butcher

Tel: 020 8487 3000

Jefferies International Ltd (Financial adviser to Flomerics)

Andres Pieczanski

Sarah McNicholas

Tel: 020 7029 8000

Oriel Securities Limited (Nominated Adviser and Corporate Broker to Flomerics)

Andrew Edwards

Michael Shaw

Tel: 020 7710 7600

Citigate Dewe Rogerson

Ginny Pulbrook

Seb Hoyle

Tel: 020 7638 9571

 

Jefferies International Limited ("Jefferies International"), which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting for Flomerics and no-one else in connection with the matters referred to herein and will not be responsible to anyone other than Flomerics for providing the protections afforded to clients of Jefferies International or for giving advice in relation to such matters.

Oriel Securities Limited ("Oriel Securities"), which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting for Flomerics and no-one else in connection with the matters referred to herein and will not be responsible to anyone other than Flomerics for providing the protections afforded to clients of Oriel Securities or for giving advice in relation to such matters.

 

 Dealing Disclosure Requirements 

Under the provisions of Rule 8.3 of the Takeover Code (the "Code"), if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Flomerics, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Nestor, they will be deemed to be a single person for the purpose of Rule 8.3. 

 

Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant securities" of Flomerics by a potential offeror or by Flomerics, or by any of their respective "associates", must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction. 

 

A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk. 

"Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. 

 

Terms in quotation marks are defined in the Code, which can also be found on the Takeover Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPGUUAPAUPRGPB
Date   Source Headline
4th Jun 20267:00 amRNSAcquisition of Helipebs Controls Ltd
28th May 20267:00 amRNS2025 Annual Report Posting & Notice of AGM
8th May 20262:28 pmRNSHolding(s) in Company
7th Apr 20267:00 amRNSAnnual Financial Report
24th Mar 20267:00 amRNSAudited Preliminary FY25 Results & Outlook update
18th Mar 20267:00 amRNSNotice of Annual results and presentation
12th Feb 20264:22 pmRNSCompletion of Acquisition
10th Feb 20264:36 pmRNSHolding(s) in Company
9th Feb 20265:25 pmRNSHolding(s) in Company
9th Feb 20264:28 pmRNSDirector/PDMR Shareholding
6th Feb 202612:08 pmRNSResult of General Meeting
22nd Jan 20264:12 pmRNSHolding(s) in Company (Correction)
22nd Jan 20262:36 pmRNSResult of Retail Offer
22nd Jan 202612:56 pmRNSHolding(s) in Company
22nd Jan 202612:48 pmRNSHolding(s) in Company
21st Jan 20262:44 pmRNSPublication of Circular
20th Jan 20263:26 pmRNSResult of Placing and Notice of General Meeting
20th Jan 20267:02 amRNSProposed Retail Offer
20th Jan 20267:01 amRNSProposed Placing And Retail Offer
20th Jan 20267:00 amRNSFull Year Trading Update & Acquisition
1st Oct 202510:39 amRNSChange of Auditor
9th Sep 20257:00 amRNSHalf-Year Report - six months ended 30 June 2025
4th Sep 20258:00 amRNSHalf-Year results - webcast presentations
29th Jul 20257:00 amRNSGroup Trading Update & Notice of Interim Results
22nd Jul 20257:00 amRNS-RNew Contract wins & Partnerships
18th Jun 20258:00 amRNS-RFlowtech wins Waterside City bridge contract
17th Jun 20252:26 pmRNSResult of AGM
27th May 20255:13 pmRNSCorrection re: timing of the 2025 AGM on 17 June
22nd May 20257:00 amRNSAvailability - FY24 Annual Report & Notice of AGM
21st May 202510:30 amRNS-RFlowtech capitalises on acquisitions opportunities
11th Apr 20257:00 amRNSDirector/PDMR Shareholding
9th Apr 20257:00 amRNSPreliminary results - year ended 31 December 2024
4th Apr 20251:19 pmRNSNotice of Results and webcast presentations
12th Feb 202511:00 amRNSDirector/PDMR Shareholding
30th Jan 20257:00 amRNSFULL YEAR TRADING UPDATE
23rd Dec 20241:53 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSPDMR - Director share dealing
26th Sep 20247:00 amRNS2024 Half-year Report & Trading update
18th Sep 20247:00 amRNSAppt of Joint Broker & Notice of Half-year results
27th Aug 20247:00 amRNSAcquisition of Thomas Wright/Thorite Group Ltd
31st Jul 20247:00 amRNSHolding(s) in Company
30th Jul 20247:00 amRNSGroup Trading Update & Notice of Interim Results
1st Jul 20247:00 amRNSChange of Adviser
19th Jun 20245:46 pmRNSHolding(s) in Company
18th Jun 20245:42 pmRNSIssue of shares to the Employees Benefit Trust
11th Jun 202412:17 pmRNSResult of AGM
31st May 202412:19 pmRNSHolding(s) in Company
22nd May 20246:03 pmRNSHolding(s) in Company
22nd May 20247:00 amRNSExercise of Warrant, Issue of new shares & TVR
20th May 20247:00 amRNSExercise of Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.